Skip to content

Construction of biobank for patients with acute pancreatitis

A prospective study on the analysis of biobank of patients with acute pancreatitis and its correlation with disease severity

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065086
Enrollment
Unknown
Registered
2022-10-27
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute pancreatitis

Interventions

Case series:None

Sponsors

Department of Gastroenterology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis of AP is clear based on clinical data, hematological indicators and imaging examinations. 2. All were admitted to the hospital for the first time and within 48 hours of onset. 3. Patients or family members were able to understand the study protocol and willing to participate in this study by providing written informed consent.

Exclusion criteria

Exclusion criteria: 1. Be less than 18 years of age or more than 85 years of age. 2. Have one or more of chronic pancreatitis, immunosuppression-related diseases, inflammatory bowel disease, cancer, irritable bowel syndrome, gastroenteritis, or necrotizing small bowel colitis. 3. Severe hypertension, diabetes mellitus, poorly controlled under medication. 4. Patients combined with severe respiratory, cardiovascular, gastrointestinal, hematologic and other primary diseases, as well as psychiatric and infectious diseases. 5. Patients combined with serious medical conditions requiring non-medical treatment such as surgery and abdominal lavage. 6. Patients combined with advanced tumors. 7. Patients with chronic renal failure caused by organic kidney disease. 8. Patients who have used antibiotics, probiotics, herbal preparations within 2 months before the onset of the disease. 9. Patients with significant deficiencies in clinical data or those who left the hospital on their own.

Design outcomes

Primary

MeasureTime frame
Clinical characteristics;Microbial diversity;Taxanomic features;Microbiological phenotypes;Functional pathways;Complete blood count;Inflammatory indicators;Comprehensive metabolic panel;Blood lipid;

Countries

China

Contacts

Public ContactDong Wu

Peking Union Medical College Hospital

wudong@pumch.cn18612671010

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026